SCHEMBL1853993

SCHEMBL1853993

N#Cc1c(OCC(N)=O)ccc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HTT P42858 3/20 0.44
HPGD P15428 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
OGG1 O15527 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 3/20 0.40
PLAU P00749 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
MMP3 P08254 2/20 0.40
RXFP1 Q9HBX9 5/20 0.40
PRNP P04156 3/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12661171 0.86 CYP1A2 (0.39) KDM4EALDH1A1MEN1KMT2AHTT
SCHEMBL15977056 0.80 HTT (0.50) KDM4EALDH1A1MEN1KMT2AHTT
SCHEMBL10588542 0.77 ALOX5 (0.47) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL1614613 0.77 KDM4E (0.72) KDM4EALDH1A1MEN1KMT2AHTT
SCHEMBL6913913 0.76 HPGD (0.39) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL2560084 0.75 MAPT (0.61) KDM4EALDH1A1MEN1KMT2AHTT
SCHEMBL25254830 0.75 MAPT (0.42) KDM4EALDH1A1MEN1KMT2AHTT
SCHEMBL6917366 0.75 CNR1 (0.48) ALDH1A1MEN1KMT2ATDP1GAA
SCHEMBL3917320 0.75 CYP1A2 (0.44) KDM4EALDH1A1MEN1KMT2AHTT
SCHEMBL7912820 0.75 NCEH1 (0.47) KDM4EALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 KDM4E 1855/4885ALDH1A1 315/4885MEN1 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.